A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 Patients.

Bakacs, Tibor; Sandig, Volker; Slavin, Shimon; Gumrukcu, Serhat; Hardy, David; Renz, Wolfgang; Kovesdi, Imre

Bakacs, Tibor; Sandig, Volker; Slavin, Shimon; Gumrukcu, Serhat; Hardy, David; Renz, Wolfgang; Kovesdi, Imre.

Afiliação

Bakacs T; HepC, Inc, 1012 Budapest, Miko str. 3. II. fl. 11., Hungary.
Sandig V; ProBioGen AG, Standort HBS Herbert-Bayer-Straße 8, 13086 Berlin, Germany.
Slavin S; Biotherapy International, The Center for Innovative Cancer Immunotherapy & Cellular Medicine, Tel Aviv, Israel, Weizmann Center, 14 Weizmann Street Floor 15, Suite 1503 Tel Aviv 64239, Israel.
Gumrukcu S; Seraph Research Institute, 2080 Century Park East, Suite 710, Los Angeles, CA 90067, USA.
Hardy D; Division of Infectious Diseases, Keck School of Medicine of The University of Southern California (USC), California, USA.
Renz W; Division of General Surgery, McGill University, Montreal, Canada.
Kovesdi I; Executive School of Management, Technology and Law, University of Sankt Gallen, Sankt Gallen, Switzerland.

Infect Disord Drug Targets ; 22(7): 1-6, 2022.

Article em En | MEDLINE | ID: mdl-35440336

Palavras-chave

COVID-19; Coronavirus; IBDV; IFN; NIH-ACTIV; R903/78; SARS-CoV-2; SIT; infectious bursal disease virus; interferon; oral treatment; safety; superinfection therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article